Y MAbs Stock Forward View
| YMABDelisted Stock | USD 8.61 0.00 0.00% |
YMAB Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Y MAbs stock prices and determine the direction of Y MAbs Therapeutics's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Y MAbs' historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time The value of RSI of Y MAbs' share price is above 80 . This entails that the stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 81
Buy Peaked
Oversold | Overbought |
Using Y MAbs hype-based prediction, you can estimate the value of Y MAbs Therapeutics from the perspective of Y MAbs response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Y MAbs Therapeutics on the next trading day is expected to be 9.49 with a mean absolute deviation of 0.40 and the sum of the absolute errors of 24.22. Y MAbs after-hype prediction price | USD 8.61 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as delisted stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
YMAB |
Y MAbs Additional Predictive Modules
Most predictive techniques to examine YMAB price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for YMAB using various technical indicators. When you analyze YMAB charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Y MAbs Naive Prediction Price Forecast For the 25th of February
Given 90 days horizon, the Naive Prediction forecasted value of Y MAbs Therapeutics on the next trading day is expected to be 9.49 with a mean absolute deviation of 0.40, mean absolute percentage error of 0.38, and the sum of the absolute errors of 24.22.Please note that although there have been many attempts to predict YMAB Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Y MAbs' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Y MAbs Stock Forecast Pattern
| Backtest Y MAbs | Y MAbs Price Prediction | Research Analysis |
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Y MAbs stock data series using in forecasting. Note that when a statistical model is used to represent Y MAbs stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 117.1448 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.3971 |
| MAPE | Mean absolute percentage error | 0.0662 |
| SAE | Sum of the absolute errors | 24.224 |
Predictive Modules for Y MAbs
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Y MAbs Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Y MAbs After-Hype Price Density Analysis
As far as predicting the price of Y MAbs at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Y MAbs or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Y MAbs, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Y MAbs Estimiated After-Hype Price Volatility
In the context of predicting Y MAbs' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Y MAbs' historical news coverage. Y MAbs' after-hype downside and upside margins for the prediction period are 8.61 and 8.61, respectively. We have considered Y MAbs' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Y MAbs is very steady at this time. Analysis and calculation of next after-hype price of Y MAbs Therapeutics is based on 3 months time horizon.
Y MAbs Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Y MAbs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Y MAbs backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Delisted Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Y MAbs, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.00 | 0.00 | 0.00 | 0.00 | 5 Events / Month | 1 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
8.61 | 8.61 | 0.00 |
|
Y MAbs Hype Timeline
Y MAbs Therapeutics is at this time traded for 8.61. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. YMAB is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at 0.0%. %. The volatility of related hype on Y MAbs is about 0.0%, with the expected price after the next announcement by competition of 8.61. About 83.0% of the company outstanding shares are owned by institutional investors. The book value of Y MAbs was at this time reported as 1.93. The company has Price/Earnings To Growth (PEG) ratio of 0.04. Y MAbs Therapeutics recorded a loss per share of 0.5. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 5 days. Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.Y MAbs Related Hype Analysis
Having access to credible news sources related to Y MAbs' direct competition is more important than ever and may enhance your ability to predict Y MAbs' future price movements. Getting to know how Y MAbs' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Y MAbs may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GTHX | G1 Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| RVNC | Revance Therapeutics | 0.01 | 6 per month | 0.00 | (0.09) | 6.38 | (5.97) | 40.39 | |
| ORTX | Orchard Therapeutics PLC | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| VIGL | Vigil Neuroscience | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CKPT | Checkpoint Therapeutics | (0.06) | 6 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CLYM | Climb Bio | 0.00 | 0 per month | 5.21 | 0.27 | 16.99 | (8.38) | 42.56 | |
| ITOS | Iteos Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SVA | Sinovac Biotech | 0.00 | 3 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BCYP | Big Cypress Acquisition | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SLGC | Somalogic | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Y MAbs Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Y MAbs stock to make a market-neutral strategy. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Y MAbs Market Strength Events
Market strength indicators help investors to evaluate how Y MAbs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Y MAbs shares will generate the highest return on investment. By undertsting and applying Y MAbs stock market strength indicators, traders can identify Y MAbs Therapeutics entry and exit signals to maximize returns.
Y MAbs Risk Indicators
The analysis of Y MAbs' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Y MAbs' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting ymab stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.04 | |||
| Semi Deviation | 1.8 | |||
| Standard Deviation | 13.05 | |||
| Variance | 170.4 | |||
| Downside Variance | 10.29 | |||
| Semi Variance | 3.23 | |||
| Expected Short fall | (5.58) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Y MAbs
The number of cover stories for Y MAbs depends on current market conditions and Y MAbs' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Y MAbs is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Y MAbs' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Y MAbs Short Properties
Y MAbs' future price predictability will typically decrease when Y MAbs' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Y MAbs Therapeutics often depends not only on the future outlook of the potential Y MAbs' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Y MAbs' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 44.3 M | |
| Cash And Short Term Investments | 67.2 M |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in YMAB Stock
If you are still planning to invest in Y MAbs Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Y MAbs' history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |